StoneWise develops the StoneMIND® platform, which utilizes AI to streamline the extraction and optimization of molecular data for drug discovery. This technology addresses the inefficiencies in traditional drug development processes by enabling rapid identification and design of drug candidates from extensive research data.
Funding
Funding not disclosed
Founders
Product
Problem
Traditional drug discovery processes are inefficient due to the challenges of extracting, structuring, and optimizing molecular data from diverse research sources. This leads to delays in identifying and designing promising drug candidates.
Solution
StoneWise offers StoneMIND®, an AI-powered platform designed to streamline molecular data extraction and optimization for pharmaceutical research and development. The platform enables rapid identification and design of drug candidates by efficiently processing extensive research data, including patents, literature, and images. StoneMIND® facilitates the creation of a high-throughput molecular screening system, a multi-dimensional molecular generation system, and a molecule optimization system based on a mapped database. The platform's tools are software-based or offered as SaaS solutions, supporting various stages of drug development.
Target Audience
The primary users are pharmaceutical researchers and drug development teams seeking to accelerate the identification and optimization of drug candidates.
Features
- AI-driven information extraction from patents, literature, and images, converting chemical structures into editable formats.
- Capability to extract chemical structures and associated physicochemical properties from images and documents.
- Batch processing of chemical structures for efficient data collection and database construction.
- Knowledge mining tools for collecting, organizing, and storing information based on specific research areas.
- Collaboration features for workflow management and knowledge sharing among research teams.
- Multi-dimensional molecular design and optimization models based on ligands, receptors, and fragments.
- High-throughput screening architecture for accelerating the discovery of potential drug molecules.
- Ability to export extracted structures and analysis results in various computer-readable formats (SDF/MOL/SMILES/XLS/PNG).